Verona Pharma: Great Year For Share Price, But Competition Threatens Bull Thesis
Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.
Truist Financial Keeps Their Buy Rating on Verona Pharma (VRNA)
In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Verona Pharma (VRNA – Research Report). The company’s ...
pharmaphorum3d
Verona’s first-in-class COPD drug ‘could transform market’
Verona Pharma has claimed FDA approval for its chronic obstructive pulmonary disease (COPD) drug ensifentrine, which has been tipped as a future blockbuster. The first-in-class dual ...
Verona Pharma price target raised to $93 from $74 at Wells Fargo
Wells Fargo analyst Tiago Fauth raised the firm’s price target on Verona Pharma (VRNA) to $93 from $74 and keeps an Overweight rating on the ...
Yahoo Finance10d
Beat the Market the Zacks Way: Verona, Visa, Starbucks in Focus
Given the prevailing market uncertainty, you may want to look at our feats to prepare better for your next action. Shares of Verona Pharma plc VRNA have gained 50.7% (versus the S&P 500’s 0.8% ...
Verona Pharma (NASDAQ:VRNA) Price Target Raised to $75.00
Verona Pharma (NASDAQ:VRNA – Free Report) had its price objective increased by HC Wainwright from $60.00 to $75.00 in a report issued on Friday,Benzinga reports. The firm currently has a buy rating on ...